0.00Open2.90Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV2.20%PremiumJan 17, 2025Expiry Date2.73Intrinsic Value100Multiplier-3DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.67Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet